|

SHR-A1811 for Injection Clinical Trials

4 actively recruiting trials

▼ -1 trial since July 2026

Also known as: SHR-A1811 group

Pipeline

Phase 1: 1Phase 2: 2Phase 3: 1

Top Sponsors

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.3
  • Henan Cancer Hospital1

Indications

  • Cancer4
  • Breast Cancer2
  • PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer1
  • HER2 Low Breast Carcinoma1
  • Solid Tumor1

Other4 trials

A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor
Phase 1
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Phase 3
A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
Phase 2
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.